Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Issued (2020 - 2024)

Historic Shares Issued for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q4 2024 value amounting to -$300.8 million.

  • 4D Molecular Therapeutics' Shares Issued changed N/A to -$300.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.3 million, marking a year-over-year decrease of 8815.86%. This contributed to the annual value of $15.3 million for FY2024, which is 8815.86% down from last year.
  • As of Q4 2024, 4D Molecular Therapeutics' Shares Issued stood at -$300.8 million.
  • In the past 5 years, 4D Molecular Therapeutics' Shares Issued ranged from a high of $281.2 million in Q2 2024 and a low of -$300.8 million during Q4 2024
  • Moreover, its 5-year median value for Shares Issued was $875000.0 (2022), whereas its average is $35.7 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Shares Issued plummeted by 4416.41% in 2021, and later soared by 1476331.43% in 2023.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Shares Issued stood at $204.7 million in 2020, then tumbled by 44.16% to $114.3 million in 2021, then tumbled by 100.77% to -$875000.0 in 2022, then surged by 41.49% to -$512000.0 in 2023, then tumbled by 58659.57% to -$300.8 million in 2024.
  • Its last three reported values are -$300.8 million in Q4 2024, $1000.0 for Q3 2024, and $281.2 million during Q2 2024.